MorphoSys
is a Germany-based biopharmaceutical company that researches and develops oncology medicines for the treatment of cancer... Read moreMorphoSys
is a Germany-based biopharmaceutical company that researches and develops oncology medicines for the treatment of cancer... Read more
News
Dec 09, 2025
Mizorammail
MorphoSys: Essential Thrombocythemia Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Jubilant Therapeutics, Kartos Therapeutics, Imago BioSciences, MorphoSys AG, PharmaEssenti
Dec 09, 2025
BioPharma Dive
MorphoSys: Novartis notches another win for drug acquired in MorphoSys deal
Oct 14, 2025
Virginianewsdesk
MorphoSys: Marginal Zone Lymphoma Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Beigene, InnoCare Pharma, Hutchmed, Incyte, Innovent, MorphoSys
Oct 07, 2025
Virginianewsdesk
MorphoSys: Myelofibrosis Market Overview: Epidemiology, Therapies, and Key Players include AbbVie, Morphosys, Geron, Bristol Myers Squibb, Kartos Therapeutics, Karyopharm Therapeutics, NS Pharma, Galecto Biotech
Oct 07, 2025
Karnatakamail
MorphoSys: Giant Cell Arteritis Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | AbbVie, Novartis, CSL, Kiniksa Pharmaceuticals, Johnson & Johnson, MorphoSys AG, Eli Lilly
Mar 12, 2025
Traderfox
MorphoSys: Echtzeit-Chart der MorphoSys AG Aktie
Dec 20, 2024
I3investor
MorphoSys: Novartis says 330 jobs hit as it closes MorphoSys sites
Nov 21, 2024
PharmaLive
MorphoSys: Novartis: launch of Morphosys drug by could be 2027 or later
Aug 29, 2024
Marketscreener
MorphoSys: MorphoSys AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
Aug 27, 2024
Morphosys
MorphoSys: Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
MorphoSys Competitors
1
2
3
4
5
6
7
8
9
10